Introduction
Gene therapy holds great promise for the treatment of deficiencies and disease, 1 with genetic modification of a variety of cell types being possible. 2, 3 Lymphocytes, in particular, can be used as vehicles for expression of proteins including enzymes, cytokines and antibodies and can be gene modified with chimeric receptors recognizing tumor antigens. Retroviral vectors are the method of choice for modifying lymphocytes since it is possible to achieve stable expression of gene products without expression of viral sequences. 4 However, although transformed cell lines can express high amounts of vectorencoded gene product, functional expression of transgene is generally low in primary lymphocytes. In this study we used a cell surface chimeric receptor as a functional reporter gene in order to assess the effect of vector modifications on transgene expression and function in primary human T cells.
Genetic modification of T cells with a chimeric receptor gene construct provides a means of generating T cells possessing an antigen specificity in addition to that encoded by their constitutive TCR. Generally, chimeric T cell receptors are fusion proteins consisting of an antigen-specific single chain immunoglobulin variable region (scFv)
Moloney murine leukemia virus LTR, and neomycin phosphotransferase expression driven by the SV40 promoter. Replacement of SV40 with an internal ribosomal entry site (IRES) increased the transgene activity of a mouse T cell line and human PBL as judged by increased cytokine release in response to antigen positive target cells. A further increase in transgene function was generated by the additional incorporation of a splice acceptor motif into the construct. Human PBL transduced with vector incorporating both IRES and intron were consistently more effective at lysing antigen positive colorectal carcinoma cells.
Gene Therapy (2002) 9, 1085-1092. doi:10.1038/sj.gt.3301734 joined to a signaling chain capable of initiating T cell activation. 5 When this molecule is expressed on the surface of T cells, the extracellular immunoglobulin fragment can bind to a surface antigen on target cells in an MHC nonrestricted manner, resulting in T cell effector function including cytokine release, and target cell lysis. This strategy has been used experimentally in mice to treat ovarian cancer, 6 breast cancer 7 and other model tumors. 8 We have also used this approach to redirect T cells to a colon carcinoma-associated antigen, EGP40, 9 expressed on colon carcinoma cells. This chimeric receptor, GA733-␥, was demonstrated to mediate colon carcinoma target cell recognition and lysis by GA733-␥-transduced human peripheral blood lymphocytes. 10 However, surface expression of GA733-␥ was not detectable on transduced human PBL by flow cytometry or radioimmunoassay. In this report we have investigated modifications to the retroviral vector used to transduce lymphocytes in an attempt to increase the activity of GA733-␥ in human PBL.
The first modification was the incorporation of an internal ribosomal entry site (IRES). IRES sequences are naturally encoded in picornaviral mRNA. Picorna viruses disrupt host mRNA translation by interrupting normal mRNA capping at the E4 subunit. 11 The viral mRNA translation then proceeds by a cap independent mechanism mediated by ribosomal recognition of the secondary RNA structure assumed by the IRES sequence. When this IRES sequence is included experimentally in a retroviral polycistronic vector, the first gene of interest is translated in a cap dependent manner, and downstream genes translated from the same mRNA with ribosomal scanning initiated at the IRES sequence. 12 Secondly, our retroviral backbone was altered by introducing a splice acceptor motif into the pre-mRNA. Eukaryotic pre-mRNA is spliced before translation based on defined splice donor and splice acceptor motifs flanking the intron. Increased gene product expression by genes with intervening sequences has been observed in several models. 13, 14 Incorporation of these two modifications in the classic MoMLV-based LXSN vector was tested for the effect on chimeric receptor expression and function. LXSN encodes two mRNA species, the gene of interest is transcribed via the 5Ј LTR promoter, whereas neomycin phosphotransferase (NPT II) is transcribed via the SV40 promoter, thereby endowing neomycin (G418) resistance to a transduced cell. 15 Replacing the SV40 promoter of the LXSN vector with an IRES sequence results in a single transcript via the 5Ј LTR which is translated from either the 5Ј cap or IRES. This construct described previously has been named G1EN. 16 The vector LXSN encodes a splice donor motif at the 5Ј region of the packaging sequence (). By introducing a splice acceptor motif at the 3Ј region of , subsequent pre-mRNA can be spliced excising the region as an intron. This sequence added to the G1EN vector has previously been entitled the SamEN vector. 17 We introduced chimeric GA733-␥ into these three vectors (LXSN, G1EN, SamEN (Figure 1) ) and determined their relative ability to impart functional antigen-specific activation and lytic potential to transduced human PBL.
Results
Retroviral titer and integration PA317-and PG13-based producer cell lines were prepared as described and the retroviral titer determined using a neomycin resistance colony-forming assay. The retroviral titer of producer cell lines containing different vectors were similar to each other within each experiment, although the average titer varied between experiments (range: 1.7 × 10 5 -3.4 × 10 6 /ml). Vector constructs were integrated into 14.1 murine lymphocyte and human PBL genomic DNA as demonstrated by southern blot of PvuII-digested genomic DNA followed by probing with neo and autoradiography (data not shown). Signals of similar intensity in each group demonstrated the integration of comparable amounts of vector DNA into each lymphocyte group. Phenotypic analysis of human PBL groups PBL were prepared in seven groups each including a nontransduced group and groups transduced with either of the three control vectors or three vectors encoding GA733-␥. PBL were expanded with mitogenic activation (OKT3) followed by culture in IL-2 and partial selection in G418 for 5 days (excluding the nontransduced PBL group which were not selected).
At 14-17 days of culture, PBL were analyzed by flow cytometry. All cultures were demonstrated to be largely CD3
Ϫ T cells (88-95%). Similar CD8 + :CD4 + ratios were observed between each group (approximately 74%:26%). The reason for the predominance of CD8 + T cells is not clear although different responses of T cell subsets to the high dose of IL-2 may lead to a more rapid expansion of CD8 + cells and perhaps enhanced selection in G418. None of the lymphocytes demonstrated a level of GA733-␥ which could be measured by flow cytometry although GA733-␥ could be easily detected on the surface of producer cells (data not shown).
GA733-␥-transduced PBL secrete GM-CSF when incubated with EGP40
+ tumor cells Human PBL transduced with GA733-␥ or control vectors were incubated with EGP40 + or EGP40 Ϫ tumor cell lines and the level of GM-CSF secreted into the supernatant measured. GM-CSF secretion has been found to correlate well with IFN-␥ production by T cells. 18 An advantage of using GM-CSF, rather than IFN-␥, is the ability to detect reactivity of both type I and II subsets of T cells. PBL transduced with pSamGA733-␥EN produced the greatest levels of GM-CSF in response to incubation with EGP40 + tumor cell lines ( Figure 3 ). PBL transduced with pLGA733-␥EN generally produced lesser amounts of GM-CSF, while a further reduction in GM-CSF production was observed from pLGA733-␥SN-transduced PBL ( Figure 3 ). Cytokine secretion was dependent on GA733-␥ expression since PBL transduced with vectors lacking GA733-␥ produced only low levels of GM-CSF. Cytokine secretion was also specific for EGP40 antigen, since EGP40
Ϫ melanoma cell lines failed to elicit GM-CSF secretion above background levels. This pattern of production was analogous to the results seen for GA733-␥-mediated IFN-␥ secretion from the murine T cell line. Results are shown for a representative donor, but all five donors demonstrated a similar pattern of recognition with the SamEN-based GA733-␥ vector imparting superior activity. 
GA733-␥-transduced PBL specifically lyse EGP40
+ tumor cells Human PBL were tested at 14-17 days of culture for their ability to specifically lyse colon cancer target cells expressing the EGP40 antigen. PBL in these culture conditions exhibited a high degree of LAK activity. In this set, as well as in the other four sets of PBL, background LAK lysis was suppressed with cold target (K562) inhibition in all PBL groups.
In Figure 4 , data are presented from one representative patient PBL against multiple cellular targets. The highest level of lysis against EGP40+ colon cancer cell lines was achieved by PBL transduced with pSamGA733-␥EN (Figure 4b-d) . When compared with these levels, a small but consistent decrease in lytic ability was observed with PBL transduced with pLGA733-␥EN. Lower levels of lysis were achieved by PBL transduced with pLGA733-␥SN. Optimal lysis was dependent on EGP40 expression since the EGP40 Ϫ melanoma cell line, 624.38mel, was not lysed above background levels by transduced PBL (Figure 4a ). Lysis was also dependent on GA733-␥ expression since PBL transduced with vectors lacking GA733-␥ produced only minimal background levels of target cell lysis. In Table 1 , data are presented from multiple patient PBL against one target cell line, CY13. pSamGA733-␥EN was more effective at imparting lytic ability on transduced PBL than pLGA733-␥EN which in turn was more effective than pLGA733-␥SN. This trend was significant with a P2 value of 0.008 when analyzed by Jonckheere's nonparametric test for trend. Values are expressed in lytic units/10 6 effector cells, with one lytic unit defined as the number of effector cells necessary for 30% lysis of tumor cells. In five of five patients lymphocytes transduced with SamGA733-␥EN were the most effective at lysing CY13. Lymphocytes transduced with LGA733-␥EN were more effective than those transduced with LGA733-␥SN in four of five patients. The order of greater to lesser function: pSamGA733-␥EN > pLGA733-␥EN > pLGA733-␥SN was statistically significant. P2 value = 0.008, Jonckheere's nonparametric test for trend.
Discussion
Gene transfer into human PBL is being pursued as a potential treatment strategy in some congenital, 19 viral 20 and neoplastic diseases. 7, 8, 21, 22 PBL have advantages over many other cell types as gene therapy vehicles in that they can be more easily accessed and transduced. They are also able to secrete proteins including cytokines and possess intrinsic effector function that can be utilized against diseased cells. Transduction frequencies of PBL can be as much as 30-50% and selection or sorting can result in close to 100% transduced populations if suitable markers are included in the transgene construct. However, functional expression of transgenes in PBL is often low and we therefore compared three retroviral vectors for their ability to confer antitumor effector function on PBL.
We have previously reported on the redirected antitumor activity of TIL transduced with a chimeric receptor specific for ovarian cancer, 6 and the specific colon carcinoma recognition by PBL transduced with a chimeric receptor, GA733-␥. 23 GA733-␥ recognizes the EGP40 antigen broadly expressed on colon cancers 24 via the chimeric receptor's extracellular immunoglobulin region. This recognition initiates T cell activation and target lysis via intracellular signaling motifs, thereby redirecting T cells to specifically attack colon cancer cells. We envision the use of this reagent in patients with metastatic colorectal cancer. PBL would be collected via leukopheresis, transduced and expanded ex vivo for adoptive transfer back to the patient. These redirected autologous T cells should then recognize colon cancer cells and mediate tumor regression.
A major obstacle to implementing this and other modalities in clinical trial is the relatively low stable gene product expression in lymphoid cells using currently available retroviral vector gene transfer techniques. 25, 26 Small increases in the expression of a gene of interest has been realized by manipulation of the ex vivo transduction culture environment. [27] [28] [29] Alteration of the retroviral envelope has enhanced the transduction of human cells, most notably the use of the gibbon ape leukemia viral envelope, 30 ,31 which we used in these human PBL transductions. However, optimal gene expression may require further modification of current retroviral vectors.
Many groups have focused on modifying these retroviral backbones by altering the promoters preceding the gene of interest. Classic vectors generally rely on the MoMLV LTR as an initiation site for the transcription of inserted genes. By the addition of short promoters and enhancers 5' to the gene of interest, some groups have demonstrated mild increases in lymphocyte transgene expression. Viral sequences inserted have included the cytomegalovirus 32, 33 and herpes simplex virus thymidine kinase 34 promoters, the polyoma early region 35 and promoters from mammalian cells have included the phosphoglycerate kinase promoter, 36 and the CD18 promoter. 33 We chose to focus on other modifications of the retroviral backbone, specifically the introduction of IRES and splicing motifs, to increase the expression and thereby the function of the chimeric GA733-␥. Morgan and colleagues 16 transferred IRES sequences of the polio and encephalomyocarditis virus into polycistronic retroviral vectors. Transduced NIH 3T3 fibroblasts exhibited capindependent expression of reporter genes. By translating both GA733-␥ and the selectable marker from the same transcript, selected cells have an increased likelihood of expressing the gene of interest (ie cells will not be selected that produce a NPTII transcript, but not a GA733-␥ transcript as is possible when using the LXSN vector). Also any inhibitory or competitive effects the SV40 promoter may have on the 5' LTR are eliminated. IRES sequences have been employed for translational control of several inserted sequences in non-lymphoid systems. 31 Some studies inserting gene constructs with IRES in lymphoid systems have demonstrated comparable expression of both reporter and selection sequences. 37, 38 We have previously used the IRES sequence in bicistronic vectors with a truncated IL-2 gene under the transcriptional control of the 5' LTR and NPTII controlled by IRES or SV40. Murine lymphocytes transduced with constructs incorporating the IRES sequence (G1IL-2EN and SAIL-2EN) sustained growth in an IL-2-free media, while lymphocytes transduced with the internal SV40 promoter (LIL-2SN) could not. 39 The introduction of an intron into a pre-mRNA sequence has mediated an elevated yield of gene product in several eukaryotic systems. [12] [13] [14] Post-transcriptional splicing directs transcripts through the splicesomal assembly pathway which stabilize some transcripts and accentuate migration to the nuclear pore. Splicing of the sequence as designed in the SamEN vector takes advantage of this phenomenon, as well as reiterating splicing of the natural MoMLV retrovirus and excising putative start sites 5' to the GA733-␥ gene. Morgan and colleagues used the SamEN vector to insert the gene for human factor VIII into NIH 3T3. Cells transduced with the transgene in a SamEN vector exhibited higher expression of factor VIII than those transduced with the transgene in the LXSN vector. 17 We have demonstrated in this study that transduction of a murine CD4
+ lymphocyte line and primary human lymphocytes with a chimeric receptor, GA733-␥, results in extension of T cell recognition to include colon cancer Gene Therapy cells expressing EGP40. T cell activation, as determined by cytokine release, was specifically enhanced when GA733-␥-expressing lymphocytes were cocultured with relevant colon cancer cell lines. In addition, these colon cancer cell lines were specifically lysed by human PBL expressing the chimeric receptor.
Redirected functional activity of lymphocytes transduced with pSamGA733-␥EN was found to be greater than that of lymphocytes transduced with pLGA733-␥EN that, in turn, was superior to lymphocytes transduced with pLGA733-␥SN. Specific recognition of colon cancer cells, as judged by cytokine release and target cell lysis, was consistently greater in PBL transduced with pSamGA733-␥EN. It is likely, from previous reports, that the inclusion of an intron into the retroviral vector resulted in greater mRNA stability, and the replacement of the SV40 promoter resulted in an increased number of chimeric receptor transcripts. Indeed, T cell function has been reported to be correlated with the number of TCR molecules on the cell surface. 40 Therefore, it seems likely that the effect of vector modifications was to increase expression of the chimeric receptor, although this could not be measured directly.
Variability was evident between PBL responses to individual colon cancer lines. For example, the LoVo colon cancer cell line consistently elicited higher cytokine release from GA7333-␥-expressing PBL than did other colon lines, while HCT116 was lysed to a greater extent. In addition, GM-CSF release from GA733-␥ expressing lymphocytes was lower when directed against CY13 than when the same lymphocytes were directed against HCT116. The reasons for this variability are unclear, although it may be due to differential expression of costimulatory or adhesion molecules on tumor target cells. Alternatively, the observed variability may be due to differing levels of EGP40 expression or differing inherent resistance of tumor cells to CTL-mediated lysis.
This system and the lymphocyte gene transfer systems discussed previously are all low expression systems. It may well be that improved functional expression with these vector modifications is most apparent in low expression systems. Indeed, in our producer lines which exhibit high expression of GA733-␥, expression is not significantly improved with the vector modifications.
In summary, expression of chimeric GA733-␥ in lymphocytes can redirect those lymphocytes to colon cancer cells. Functional activity of chimeric GA733-␥ was greatest in lymphocytes transduced with the modified retroviral vector, pSamGA733-␥EN, that incorporates both an IRES and intronic sequence.
Materials and methods

Cell culture
The GP+E86, PA317 and PG13 retroviral producer cell lines (all from ATCC, Rockville, MD, USA) and subsequent producer lines were cultured in DMEM supplemented with additives consisting of: 10% fetal calf serum (FCS) (Biofluids, Rockville, MD, USA), 2 mM glutamine, and antibiotics consisting of the following: 100 units/ml penicillin, 100 g/ml streptomycin (all from Biofluids), 50 g/ml gentamycin sulfate (BioWhittaker, Walkersville, MD, USA), 1.25 g/ml amphotericin B (Fungizone, Life Technologies). The murine T cell line 14.1 (generously provided by Dr J Berzofsky, NIH, Bethesda, MD, USA), a clonal CD4 + cell line specific for an epitope of sperm whale myoglobin (SWM), was cultured in a 1:1 mixture of EHAA and RPMI (Biofluids), with additives and 300 IU/ml IL-2 (Chiron, Emeryville, CA, USA), 1× NEAA, 1 mM sodium pyruvate (both from Biofluids), 5 × 10 Ϫ5 M 2-mercaptoethanol (Gibco Laboratories, Grand Island, NY, USA). Peripheral blood mononuclear cells (PBMC) from normal healthy adult volunteers were isolated over a Ficoll-Hypaque density gradient (LSM, Organon Teknika, Durham, NC, USA) and resuspended in RPMI with 10% human AB serum (male, heat inactivated, Sigma Chemical, St Louis, MO, USA), 600 U/ml IL-2 and antibiotics. The EGP-40 negative cell lines, Daudi, a human lymphoma line; K562, a human erythroleukemia cell line; 624.38mel, and 888mel human melanoma cell lines; and the EGP + cell lines HCT 116, CY13 and LoVo human colon cancer lines were cultured in RPMI with additives. MCA 102 and 24 JK and EGP40 transduced lines derived from these are murine fibrosarcomas cultured in DMEM with additives.
Retroviral vectors
Previously, we have discussed the generation of the gene encoding the chimeric receptor GA733-␥ and its introduction into the LXSN retroviral backbone to produce pLGA733-␥SN. 23 The G1EN retroviral vector (generously provided by R Morgan, NCI, Bethesda, MD, USA) replaces the SV40 promoter of LXSN, which drives neomycin phosphotransferase expression, with an encephalomyelitis virus IRES. The SamEN retroviral vector was constructed, as described previously, by introduction of a splice acceptor motif derived from the 3' end of the env sequence of wild-type MoMLV into the NotI site of pG1EN. The GA733-␥ gene with leader sequence was isolated from pcDNA3-GA733-␥ by SnaBI/XhoI digest, and ligated into SnaBI/XhoI-digested G1EN and SamEN to construct pLGA733-␥EN and pSamGA733-␥EN, respectively. Vector manipulations were confirmed to be accurate by sequence analysis. A schematic representation of the vectors is given in Figure 1 .
Retrovirus production A mixture of GP+E86 ecotropic (3 × 10 5 ) and PA317 amphotropic (2 × 10 5 ) producer cell lines in 100-mm tissue culture plates was transfected by the calcium phosphate method using a commercially available kit (Stratagene, La Jolla, CA, USA). This was accomplished using 30 g of the plasmids described above (pLXSN, pLGA733-␥SN, pG1EN, pLGA733-␥EN, pSamEN, and pSamGA733-␥EN). Bulk transduced cell lines were selected with 600 g/ml of G418 (Geneticin; Gibco Laboratories, Grand Island, NY, USA). Cell supernatants containing retroviral RNA packaged in amphotropic envelope were recovered from nearly confluent cultures of the resultant PA317 producer lines (without G418) and used to transduce the PG13 producer line (5 × 10 5 cells per line) daily for 3 days. PG13 lines were prepared for each of the six vectors studied and selected in 600 g/ml G418. Filtered (0.45 m) PG13 supernatants containing retroviral RNA packaged in the gibbon ape leukemia virus envelope were recovered from nearly confluent flasks of selected bulk producer lines following 16-24 h of culture (32°C, 5% CO2) and used immediately for lymphocyte transductions. The retroviral titer of supernatants was determined using a G418 resistance colony assay: 3T3 (for PA317 supernatant) or HCT116 cells (for PG13 supernatant) were seeded into six-well plates (2.5 × 10 4 /well) and incubated with dilutions of producer cell supernatant containing 8 g/ml polybrene. Two days later media containing G418 (1 mg/ml) was added. After a further 7 days, cells were stained with methylene blue and colonies counted.
Murine lymphocyte transduction
Murine lymphocytes were transduced with the six retroviral constructs by incubation of 5 × 10 5 lymphocytes in ecotropic producer cell supernatant supplemented with IL-2 (300 IU/ml) and polybrene (8 g/ml), and cultured in 24-well plates (32°C, 5% CO 2 ). One half of the culture medium was aspirated from the wells and replaced with fresh retroviral supernatant, IL-2, and polybrene every 12 h for 72 h totaling six supernatant exposures each. The lymphocytes were subsequently resuspended in fresh media without polybrene, but with G418 at 800 g/ml (37°C, 5% CO 2 ). Cells were maintained at a density of 5-10 × 10 5 cells/ml and resuspended in fresh media without G418 48 h before cytokine release assays.
Human PBL PBMC from five normal healthy adult volunteers were stimulated with OKT3 (10 ng/ml) and IL-2 (600 IU/ml), and cultured in 24-well plates for 72 h. Washed PBL were then resuspended (1 × 10 6 /ml) in fresh PG13 producer cell supernatant containing retrovirus, and supplemented with IL-2 (600 IU/ml) and polybrene (8 g/ml) in sixwell plates, centrifuged for 1 h (1000 g, 32°C) followed by incubation (37°C, 5% CO 2 ). One half of the culture medium was aspirated and replaced with fresh supernatant (supplemented with IL-2 and polybrene) every 12 h followed by centrifugation under the same conditions for a total of four supernatant exposures. Human PBL were then resuspended in fresh media for 24 h, followed by fresh media with G418 (500 g/ml) for 5 days. PBL were then transferred to fresh media until day 14-17 when assayed for activity. Throughout culture manipulations, cell density was maintained at approximately 1 × 10 6 /ml by splitting every 2-3 days.
Flow cytometry
At day 14, PBL were stained for flow cytometric analysis with the rat monoclonal antibody FG1 specific for the GA733 idiotype (generously provided by Dr Dorothy Herlyn, Wistar Institute, Philadelphia, PA, USA) followed by FITC-conjugated goat anti-rat immunoglobulin. PBL were also stained with FITC-or PE-conjugated mouse monoclonal antibodies recognizing human CD3, CD56, CD4 and CD8 (Becton Dickinson, Lincoln Park, NJ, USA). 
GM-CSF release
Human PBL were analyzed for their ability to be specifically activated through GA733-␥ in a cytokine release assay. PBL (2 × 10 5 ) were co-cultured with the EGP40+ cell lines LoVo, HCT116, CY13, or the EGP40Ϫ, 624.38mel and 888mel tumor cells (1 × 10 5 ) in duplicate wells (96-well plates). Media harvested from these wells at 24 h was analyzed for GM-CSF concentration using a commercially available ELISA kit (R&D, Minneapolis, MN, USA).
Tumor cell lysis
Transduced human PBL were assessed for their ability to specifically lyse tumor targets using a 51 Cr release cytotoxicity assay described previously. 6 Tumor targets labeled with 
Statistical analysis
In order to quantitatively determine the relative magnitude of cytolytic potential imparted on T cells by the constructs pSamGA733-␥EN, pLGA733-␥EN and pLGA733-␥SN, cytolysis data from five patients against the CY13 target cell line was analyzed using Jonckheere's nonparametric test for trend. The comparative ability of the constructs to induce GM-CSF secretion was analyzed using the Factorial ANOVA test performed on data from two patients and the target cell lines HCT 116, CY13 and LoVo.
